WOELFEL RANDY sold (to issuer) $107K of WLKP

WOELFEL RANDY sold (to issuer) 5,005 shares of Westlake Chemical Partners LP (WLKP) at $21.35 ($0.11M total) on 2026-08-06.

Original reporting
SEC EDGAR · WOELFEL RANDY
Published Aug 7, 2026, 11:34 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 11:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$WLKP
Neutral
high confidence
Mentioned
$WLKP
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WLKPNeutralLow
01

Why it matters

The newest fact is the reported sale to the issuer of 5,005 shares at $21.3500 on 2026-08-06, with holdings after transaction of 23,913 shares.

02

Market read

Traders may note insider activity, but there is no accompanying fundamental update, guidance change, or corporate action beyond the transaction itself.

03

What to watch

Insider sales can be driven by liquidity needs, tax planning, or standardized issuer buyback mechanics; the filing provides no rationale or linkage to performance.

Relevance 4/10Novelty 2/10Timing: filed 2026-08-07 after-hours/early session window (Form 4 timestamp)

Background

The article is a SEC Form 4 insider transaction disclosure for Westlake Chemical Partners LP (WLKP).

Company-level read

Ticker impact

$WLKPNeutralHigh confidence
Context

Westlake Chemical Partners LP disclosed an insider sale to the issuer of 5,005 shares at $21.3500 on 2026-08-06 via Form 4.

Expected impact

Low likelihood of a sustained price move based solely on this Form 4 sale.

Evidence & confidence

The filing is an insider sale to the issuer (buyback participation style) with no 10b5-1 plan and no accompanying operational or financial update.

Market effects

Minimal, as the disclosure is company-specific insider trading without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The lack of a stated 10b5-1 plan could be interpreted as discretionary selling, but the transaction is explicitly a sale to the issuer, which often reduces interpretive weight.

Key entities

  • Westlake Chemical Partners LP

    Subject of the Form 4 insider transaction disclosure (WLKP).

  • WOELFEL RANDY

    Director who sold shares to the issuer under code D.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WLKMed

Westlake Chemical Partners LP Q3 2026 Earnings Call Summary

Westlake Chemical Partners LP reported Q3 2026 net income growth due to higher production and sales volumes. Distributable cash flow rose to $18 million, with a trailing 12-month coverage ratio of 1.09x. Management expects modest benefits from rising ethylene prices in Q4 2026 and plans to begin renegotiating the Ethylene Sales Agreement next year. The company maintains a conservative leverage ratio of 1x and has sustained distributions for 49 consecutive quarters.

$WLKPMed

Westlake Chemical Partners LP Announces Third Quarter 2026 Results

Westlake Chemical Partners LP (WLKP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 WESTLAKE CHEMICAL PARTNERS LP Contact—(713) 585-2900 Investors—Jeff Holy Media—L. Benjamin Ederington Westlake Chemical Partners LP Announces Third Quarter 2026 Results • Declared quarterly distribution of $0.4714 per unit; 49 th consecutive quarterly distribution HO

$WLKPMed

Westlake Chemical Partners Q2 Earnings Call Highlights

Westlake Chemical Partners (NYSE:WLKP) reported Q2 net income of $14 million, or $0.40 per unit, and distributable cash flow of $18 million, or $0.50 per unit. The quarterly distribution was $0.4714 per unit, with a 1.04x trailing coverage ratio. Consolidated net sales were $297 million. The partnership extended revolvers through 2031 and leadership shifted to John Bochert as CFO.

$WLKPMed

Westlake Chemical Partners LP Announces Second Quarter 2026 Results

Westlake Chemical Partners LP (WLKP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 WESTLAKE CHEMICAL PARTNERS LP Contact—(713) 585-2900 Investors—Jonathan Baksht Media—L. Benjamin Ederington Westlake Chemical Partners LP Announces Second Quarter 2026 Results • Declared quarterly distribution of $0.4714 per unit; 48 th consecutive quarterly distribu